(NASDAQ: XXII) 22nd Century Group, Inc. -Regains Compliance with Nasdaq Stockholders' Equity Requirement

22nd Century Group, Inc. (NASDAQ: XXII) Breaking NEWS 22nd Century Regains Compliance with Nasdaq Stockholders' Equity Requirement 10XProTrader Member, This is Kevin Vander with "10XProTrader", we have a new profile for you. It's, [22nd Century Group, Inc. (NASDAQ: XXII)]( [News Release]( 22nd Century Regains Compliance with Nasdaq Stockholders' Equity Requirement Newsfile Corp. Tue, Oct 8, 2024, 8:00 AM EDT4 min read In this article: Mocksville, North Carolina--(Newsfile Corp. - October 8, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it has received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). This confirmation follows the Company's successful efforts to improve its balance sheet and liquidity by completing new equity offerings, while reducing outstanding liabilities and debt through various forms of settlement with creditors. As a result, the Company now meets Nasdaq's stockholders' equity minimum requirement of at least $2.5 million. Larry Firestone, Chief Executive Officer said, "We are pleased to receive Nasdaq's notification confirming 22nd Century's regained compliance with the minimum stockholders' equity requirement. Over the past two quarters, we have made significant strides in improving our balance sheet and expanding our business. During this period, we have raised $11.6 million of equity proceeds and de-levered our balance sheet, among other activities, to reach the equity minimum of $2.5 million. We remain committed to ensuring our listing compliance and creating long-term shareholder value." About 22nd Century Group, Inc. 22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption. We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them smoke less. VLN® is the world's first and only combustible cigarette to receive a Modified Risk Tobacco Product designation from the FDA, which the FDA has mandated be described as a product that Helps You Smoke Less®. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether. Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion. Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets. Our mission is to sell the last cigarette before the 22nd Century. VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC. Learn more at [xxiicentury.com]( on [X (formerly Twitter)]( on [LinkedIn]( and on [YouTube](. Learn more about VLN® at [tryvln.com](. Cautionary Note Regarding Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. --------------------------- Since our initial update, XXII has published two press releases showing how its industry-changing VLN® (Very Low Nicotine) cigarettes could be the best-positioned product to seize a sizable share of a market targeting customers wanting all the pleasure of smoking but without the full measure of nicotine. The product is more than innovative; it serves a harm-reduction market that is growing in popularity. Serving the harm-reduction category boom... The appealing part of that category to consumers is that the products, like XXII's VLN®, don't deprive users of the satisfaction expected. In this case, XXII's VLN® cigarettes contain 95% less nicotine than traditional nicotine delivery products and are designed to help smokers reduce their nicotine intake without sacrificing the smoking experience they enjoy. While that's great for users, XXII also presents an excellent opportunity for investors. Here's why. 22nd Century's VLN® is the only FDA-approved cigarette that can be marketed as a Modified Risk Tobacco Product (MRTP). That distinction allows them to sell its product as one that "Helps You Smoke Less®," which resonates with smokers who aren't ready to quit but want to manage their nicotine consumption. The company is capitalizing on that designation. On September 25th, XXII announced a commitment from an existing customer to supply their filtered cigar products. As part of this deal, 22nd Century Group will assume production of all the customer's filtered cigar products using an in-house predicate blend. Initial shipments are expected in the fourth quarter of 2024, with volumes anticipated to be 200,000 cartons or more annually. Earlier this year, XXII signed an agreement with the same customer for its export conventional cigarette products business. That deal could add 20% to the overall contract manufacturing business volumes, which the company said should start to ramp up this year. Also in September, XXII announced an agreement to supply its Moonlight branded cigarettes to the Southeast Asian market, a deal that could grow its manufacturing volumes by more than 30% over the next 15 months. These updates add to others that show XXII is expanding its market presence in key markets. As importantly, with the company well-positioned to generate solid cash flows, its target of being cash flow positive by early 2025 is in the crosshairs. Products are available in thousands of retail locations... Currently, VLN® products are available in over 5,000 stores across 26 U.S. states. More could follow. XXII said it plans to extend its VLN® brand with new "flanker" products, much like Coca-Cola extended its product line with Diet Coke, and Heineken introduced a zero-alcohol version of its beer. These new products would diversify the company's product portfolio while strengthening its brand and leadership positions in the reduced-nicotine category. Additionally, if XXII stays on its business course and meets expectations, the result could be XXII ushering in an entirely new product category within the tobacco industry, similar to how light beer offered a lower-calorie alternative for beer drinkers, and decaf coffee gave caffeine lovers a choice. 10X Pro Trader subscribers- it's easy to appreciate XXII for the products it sells. After all, they are well-designed and serve a potentially lucrative market. However, we aren't featuring XXII for that reason. 10X Pro Trader is all about introducing innovative companies that also present attractive investment opportunities. We did that with this company in September. The value proposition looks even more significant after a pullback in price despite publishing value-driving updates. A value proposition exposed... That assumption is based on several things. Foremost, XXII's VLN® cigarettes, as a breakthrough harm-reduction product, have the potential and early-mover advantage to disrupt the tobacco industry, similar to how decaf coffee and light beer revolutionized their respective markets. Add to that potential the FDA's MRTP designation, and XXII looks competitively better positioned than any other company to develop this market. We've never shied away from introducing companies that do things differently from their competitor herd. In fact, we embrace those innovators, especially when they present compelling investment opportunities. About 22nd Century Group, Inc. (NASDAQ: XXII) 22nd Century Group, Inc. (Nasdaq: XXII) is a next-generation plant biotechnology company, focused on improving human health through plant science. Using their breakthrough, patent-protected IP to control nicotine biosynthesis in the tobacco plant, they have developed the first market-ready, reduced nicotine content (RNC) tobacco plants and cigarettes containing 95% less nicotine. They received the first and only FDA MRTP authorization for a combustible cigarette in December 2021. The sole function of their cigarettes is to make it easier to reduce the number of cigarettes smoked. In tobacco, 22nd Century employs a unique and innovative platform of modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding, to deliver healthier solutions for pressing issues. They create new, proprietary plants with select alkaloid, terpenoid, and flavonoid profiles, improved yields, and valuable agronomic traits for the life science and consumer products industries. Learn more at [xxiicentury.com](  A game-changer in the reduced harm landscape... Its innovative VLN® cigarettes empower smokers to reduce nicotine consumption without sacrificing the smoking experience they know. That difference is a competitive advantage. And it's not just another nicotine delivery system; it's giving smokers the ability to make informed decisions about their nicotine intake. The value driver in its mission to create market and shareholder value is the FDA-approved VLN® cigarette, which contains 95% less nicotine than traditional cigarettes.  Here's the more important consideration from an investor perspective- XXII's VLN® cigarette is uniquely positioned as the only combustible cigarette authorized to be marketed as a Modified Risk Tobacco Product, carrying the powerful message that it "Helps You Smoke Less®." Learn more about VLN® at [tryvln.com](. 22nd Century Group, Inc. may be paving the way for a new standard in smoking that reflects progress, not replacement. If successful, this sub-dollar company could be behind a shift that could disrupt the entire tobacco landscape. That mission is in progress, evidenced by XXII's vision translating to real market traction. According to updates, sales of VLN® have exceeded expectations in many of the test markets established in 2023, leading XXII to expand its sales and marketing operations. Currently, VLN® is available in over 5,000 stores across 26 states, but that's just the beginning. [The first cigarette that helps you smoke less.]( VLN® is an FDA authorized, new-to-market product with 95% less nicotine than traditional cigarettes. This innovative product aids in reducing your smoking by considerably lowering your nicotine consumption. - First of Its Kind: The only tobacco cigarette authorized by the FDA to help you smoke less, VLN® offers an entirely new approach. - A Familiar Smoking Experience: VLN® cigarettes smoke, taste, and smell like what you're used to, just with less nicotine. VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC. [tryvln.com](  All of the above contributes to an evidence-based case for why XXII needs to be considered for a growth stock portfolio. Remember, XXII's VLN® cigarettes don't deprive smokers of satisfaction. Instead, they allow smokers to enjoy a smoking routine with the added benefit of significantly reduced nicotine exposure. That delivers more than a win-win proposition—it also fills a gap in the harm-reduction nicotine market ripe for the taking. And that's exactly what XXII is in the process of doing. With its VLN® a trailblazer in the space, similar to early category creators in other industries that changed consumer behavior by meeting them where they are, not where companies wanted them to be. If you missed some of my recent big "10x Alerts"  I strongly suggest you get ready for our explosive new breakout alert... Because, you don't want to miss another winner with tremendous upside potential! Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: [( [( [( [( [( [( [( [( [( [www.stocktitan.net/news/XXII/22nd-century-updates-strategic-growth-initiatives-for-h5vt2iq9hh35.html#:~:text=22nd%20Century%20Group%20plans%20to,their%2095%25%20less%20nicotine%20tobacco.]( [22nd Century Updates Strategic Growth Initiatives for VLN (yahoo.com)]( [22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume (yahoo.com)]( [22nd Century Announces New Branded Products Order with Customer for Southeast Asia (yahoo.com)]( [22nd Century Satisfies IP Licensing and Sponsored Research Obligations to NCSU Through 2025 in an Equity Transaction (yahoo.com)]( [Cigarette Harm Reduction | 22nd Century Group - XXII (xxiicentury.com)]( [Our Process | 22nd Century Group - XXII (xxiicentury.com)]( [Our Engine | 22nd Century Group - XXII (xxiicentury.com)]( [XXII - Overview (ir365connect.com)]( [xxii-investor-deck-sept-2024.pdf (ir365connect.com)]( [22nd Century Updates Strategic Growth Initiatives for VLN | XXII Stock News (stocktitan.net)]( [Home Page | 22nd Century Group | XXII (xxiicentury.com)]( [22nd Century Group, Inc. (XXII) Stock Historical Prices & Data - Yahoo Finance]( [22nd Century Regains Compliance with Nasdaq Stockholders' Equity Requirement (yahoo.com)]( You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2024 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2024 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.